Insider Selling: Nkarta, Inc. (NASDAQ:NKTX) Insider Sells $19,003.60 in Stock

Nkarta, Inc. (NASDAQ:NKTX) insider David Shook sold 8,638 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $19,003.60. Following the sale, the insider now directly owns 190,955 shares of the company’s stock, valued at approximately $420,101. The trade was a 4.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Nkarta Stock Performance

NASDAQ NKTX opened at $2.47 on Monday. The company has a market capitalization of $174.31 million, a PE ratio of -1.31 and a beta of 0.85. Nkarta, Inc. has a 52-week low of $2.08 and a 52-week high of $16.24. The company has a 50-day simple moving average of $2.52 and a 200 day simple moving average of $4.18.

Wall Street Analysts Forecast Growth

NKTX has been the subject of several analyst reports. HC Wainwright lowered their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Rodman & Renshaw assumed coverage on Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price target for the company. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Needham & Company LLC lowered their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 8th. Finally, Mizuho cut their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.00.

Institutional Trading of Nkarta

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of Nkarta by 110.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after buying an additional 5,243 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in Nkarta during the third quarter valued at about $33,000. The Manufacturers Life Insurance Company boosted its position in Nkarta by 92.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company’s stock worth $122,000 after purchasing an additional 9,975 shares during the period. Forefront Analytics LLC purchased a new position in shares of Nkarta in the second quarter worth about $70,000. Finally, State Street Corp raised its position in shares of Nkarta by 1.4% in the third quarter. State Street Corp now owns 1,098,062 shares of the company’s stock valued at $4,963,000 after purchasing an additional 15,569 shares during the period. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.